Education
About Us
Working with TipRanks
Follow Us
TELA Bio (TELA)
NASDAQ:TELA
TELA Stock Chart & Stats
$1.15
$0.04(1.41%)
At close: 4:00 PM EST
$1.15
$0.04(1.41%)
Day’s Range― - ―
52-Week Range$0.86 - $3.10
Previous CloseN/A
Volume34.27K
Average Volume (3M)90.44K
Market Cap
$52.55M
Enterprise Value$94.93M
Total Cash (Recent Filing)$29.71M
Total Debt (Recent Filing)$42.02M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Mar 19, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding44,530,537
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.03
Price to Sales (P/S)1.24
P/FCF Ratio-2.02
Enterprise Value/Market Cap1.81
Enterprise Value/Revenue1.23
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda-2.87
Forecast
1Y Price Target
$3.31Price Target Upside187.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth PotentialReaching the milestone of $100M in revenues brings the company closer to profitability and increases the tangibility of TELA as a take-out candidate.
LeadershipThe appointment of Jeff Blizard, who brings extensive leadership experience from Abiomed, is seen as a positive move for TELA's growth strategy.
Product SuccessNew products in both PRS and Hernia are anticipated to contribute to growth reacceleration.
Bears Say
Financial ChallengesDespite controlling some costs, the operating loss was higher than anticipated, suggesting financial challenges.
Funding NeedsThe company may need another round of financing to fund operations, which could negatively impact the stock.
Sales Force TurnoverThe departure of 11 of 69 high-performing territory managers led to a significant drop in sales.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.86 and its highest was $3.10 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $52.55M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Mar 19, 2026 which is in 91 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on Nov 13, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.003.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.18.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,530,537 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went down -9.91%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TELA Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.31 (187.83% Upside)
$3.31 (187.83% Upside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.18%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as revenue growth and operational efficiency improvements, alongside challenges including lower than expected Q3 results and ongoing net losses. The sentiment is balanced with strategic steps being taken to improve future performance.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$3.31
▲(187.83% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
32.67% Insiders
7.06% Mutual Funds
50.75% Other Institutional Investors
5.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---